Do you have ulcerative coltis?
If you have moderate to severe ulcerative colitis (UC) and you live in the Los Angeles area, you may be eligible to participate in a new clinical trial looking at the safety, tolerability, pharmacokinetics and efficacy of a potential new oral medication called AT-177. The trial is 8 weeks long with a 4 week follow up. It is being conducted at UCLA. All patients will be randomly assigned to one of three doses of the active drug AT-177. Patients must be between 18 and 80 years of age and meet specific inclusion and exclusion criteria in order to participate. There is no cost to participate.
Please enter your details and we will connect you if you meet the eligibility criteria.
Disclaimer - Choosing to participate in a study is an important personal decision. Talk with your doctor, family members or friends when considering to join a study. AT177 has not been demonstrated to be safe or effective for any indication and is not available for sale in the United States or any other country.
Your personal information is being requested to allow an initial assessment to be made about your potential eligibility for participation in a clinical trial. By submitting the requested information, you are consenting for your personal and health information to be viewed by representatives from Azora Therapeutics and its affiliates, and disclosed to a relevant trial site for further assessment. Your data will be stored on our servers until completion of the study. It will not be used for any purposes other than the purpose stated above. Potential participants should contact us if they wish to have their information updated or removed from theses systems prior to the completion of the study.